



Viveve Medical, Inc. (Nasdaq: VIVE)

345 Inverness Drive South
Building B, Suite 250
Englewood, CO 80112
T: 720-696-8100

Share Price	\$3.11
Volume	258.64k
Shares Outstanding	31,488,506
Market Cap	\$97.93m
52 Week High	\$6.00
52 Week Low	\$1.60

as of 08/20/2018



Overview

Viveve Medical, Inc. is a women's intimate health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System, that delivers the Viveve treatment, incorporates clinically-proven cryogen-cooled, monopolar radiofrequency (CMRF) technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate robust neocollagenesis in a single 30-minute in-office session.

International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications from over 55 countries. Viveve received approval of an Investigational Device Exemption (IDE) application from the U.S. Food and Drug Administration (FDA) in March of 2018 to proceed with VIVEVE II, a multicenter, randomized, double-blind, sham-controlled study to assess improvement of sexual function in women following childbirth. Initiation of the trial began in the second quarter of 2018 and if successful, could support a marketing application for a new U.S. commercial indication. Currently, in the United States, the Viveve System is cleared by the FDA for use in general surgical procedures for electrocoagulation and hemostasis.

Viveve has submitted an Investigational Trial Application to the Canadian Ministry of Health and plans to submit an IDE to the FDA to conduct two independent multicenter randomized registration trials (LIBERATE-International and LIBERATE-U.S. respectively) for use of the CMRF device in stress urinary incontinence treatment.

Disclaimer

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.

InControl Products by Viveve are FDA cleared medical devices that treat stress, urge, and mixed incontinence conditions and products to improve pelvic floor strength. Viveve exclusively distributes InControl Medical's products to healthcare providers in the United States.

For more information visit Viveve's website at www.viveve.com.

Management Team

Scott Durbin
Chief Executive Officer and Director

James Atkinson
Chief Business Officer and President

Recent News

Tuesday, August 14, 2018 - 08:28 AM
[Viveve Initiates LIBERATE-International Trial for Improvement of Stress Urinary Incontinence](#)

Thursday, August 09, 2018 - 04:02 PM
[Viveve Reports Second Quarter 2018 Financial Results and Provides Corporate Update](#)

Tuesday, August 07, 2018 - 08:28 AM
[Viveve Announces FDA Approval to Continue VIVEVE II Clinical Study](#)

Thursday, August 02, 2018 - 08:28 AM
[Viveve to Announce Financial Results for Second Quarter 2018 and Host Conference Call](#)

Tuesday, July 10, 2018 - 08:28 AM
[Viveve Reports Preliminary Second Quarter 2018 Revenue of \\$5.5 million](#)